Lista de obras - Stéphane de Botton - Dominio Público Uruguay

A novel effect of DNA methyltransferase and histone deacetylase inhibitors: NFkappaB inhibition in malignant myeloblasts

artículo científico publicado en 2008

AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic IDH2 Mutations.

artículo científico publicado en 2017

Acute leukemia during pregnancy: a report on 37 patients and a review of the literature.

artículo científico publicado en 2005

Additional chromosomal abnormalities in patients with acute promyelocytic leukaemia (APL) do not confer poor prognosis: results of APL 93 trial

An 18-case outbreak of drug-resistant Pseudomonas aeruginosa bacteriemia in hematology patients

artículo científico publicado en 2006

An activating mutation in the CSF3R gene induces a hereditary chronic neutrophilia

scientific article published on 20 July 2009

Are PU.1 mutations frequent genetic events in acute myeloid leukemia (AML)?

artículo científico publicado en 2002

Arsenic trioxide is required in the treatment of newly diagnosed acute promyelocytic leukemia. Analysis of a randomized trial (APL 2006) by the French Belgian Swiss APL group

article

Azacytidine in combination with tyrosine kinase inhibitors induced durable responses in patients with advanced phase chronic myelogenous leukemia.

artículo científico publicado en 2017

BCOR and BCORL1 mutations in myelodysplastic syndromes and related disorders.

artículo científico publicado en 2013

Central nervous system involvement in adult acute lymphoblastic leukemia at diagnosis and/or at first relapse: results from the GET-LALA group

scientific article published on 27 May 2008

Characterization of novel genomic alterations and therapeutic approaches using acute megakaryoblastic leukemia xenograft models

artículo científico publicado en 2012

Chromosomal minimal critical regions in therapy-related leukemia appear different from those of de novo leukemia by high-resolution aCGH.

artículo científico publicado en 2011

Clonal heterogeneity of acute myeloid leukemia treated with the IDH2 inhibitor enasidenib

scientific article published on 16 July 2018

Comparison of high-dose cytarabine and timed-sequential chemotherapy as consolidation for younger adults with AML in first remission: the ALFA-9802 study

artículo científico publicado en 2011

Computer tomography in pulmonary invasive aspergillosis in hematological patients with neutropenia: an useful tool for diagnosis and assessment of outcome in clinical trials.

artículo científico publicado en 2009

Concurrent Etoposide, Steroid, High-dose Ara-C and Platinum chemotherapy with radiation therapy in localised extranodal natural killer (NK)/T-cell lymphoma, nasal type.

artículo científico publicado en 2015

Differentiation Syndrome Associated With Enasidenib, a Selective Inhibitor of Mutant Isocitrate Dehydrogenase 2: Analysis of a Phase 1/2 Study.

artículo científico publicado en 2018

Discovery of AG-120 (Ivosidenib): A First-in-Class Mutant IDH1 Inhibitor for the Treatment of IDH1 Mutant Cancers.

artículo científico publicado en 2018

Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML

article

Ecto-calreticulin in immunogenic chemotherapy

artículo científico publicado en 2007

Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia

artículo científico publicado en 2017

Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response

artículo científico

Erlotinib and gefitinib for the treatment of myelodysplastic syndrome and acute myeloid leukemia: a preclinical comparison

artículo científico publicado en 2008

Erlotinib antagonizes ABC transporters in acute myeloid leukemia

artículo científico publicado en 2012

Erlotinib exhibits antineoplastic off-target effects in AML and MDS: a preclinical study

artículo científico publicado en 2007

Erratum to: Flt3 receptor inhibition reduces constitutive NFκB activation in high-risk myelodysplastic syndrome and acute myeloid leukemia

scientific article published on 01 December 2015

Favorable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia: a study from the Acute Leukemia French Association (ALFA)

artículo científico publicado en 2002

Flt3 receptor inhibition reduces constitutive NFkappaB activation in high-risk myelodysplastic syndrome and acute myeloid leukemia

artículo científico publicado en 2008

Hypomethylating agents reactivate FOXO3A in acute myeloid leukemia

artículo científico publicado en 2011

IDH1 and IDH2 mutations as novel therapeutic targets: current perspectives

artículo científico publicado en 2016

Immune stimulation during chemotherapy increases incidence of acute graft versus host disease in acute myeloid leukemia: A study on behalf of SFGM-TC and ALFA.

artículo científico publicado en 2017

Impact of additional genetic alterations on the outcome of patients with NPM1-mutated cytogenetically normal acute myeloid leukemia.

artículo científico publicado en 2014

Improved outcome of acute promyelocytic leukemia with high WBC counts over the last 15 years: the European APL Group experience.

artículo científico publicado en 2009

Inherited transmission of the CSF3R T618I mutational hotspot in familial chronic neutrophilic leukemia

scientific article published on 01 December 2019

Invasive cutaneous infection due to Scopulariopsis brevicaulis unsuccessfully treated with high-dose micafungin in a neutropenic patient.

artículo científico publicado en 2016

Is Cytarabine Useful in the Treatment of Acute Promyelocytic Leukemia? Results of a Randomized Trial From the European Acute Promyelocytic Leukemia Group

article by Lionel Adès et al published 20 December 2006 in Journal of Clinical Oncology

Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia

scientific article published on 01 February 2020

Liposomal amphotericin B in combination with caspofungin for invasive aspergillosis in patients with hematologic malignancies: a randomized pilot study (Combistrat trial).

artículo científico publicado en 2007

Long-term follow-up of European APL 2000 trial, evaluating the role of cytarabine combined with ATRA and Daunorubicin in the treatment of nonelderly APL patients

artículo científico publicado en 2013

Molecular determinants of immunogenic cell death: surface exposure of calreticulin makes the difference

artículo científico publicado en 2007

Monitoring antibiotic-resistant enterobacteria faecal levels is helpful in predicting antibiotic susceptibility of bacteraemia isolates in patients with haematological malignancies.

artículo científico publicado en 2015

Mutation allele burden remains unchanged in chronic myelomonocytic leukaemia responding to hypomethylating agents

artículo científico publicado en 2016

Mutational profiling of isolated myeloid sarcomas and utility of serum 2HG as biomarker of IDH1/2 mutations

artículo científico publicado en 2018

Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes.

artículo científico publicado en 2012

Myelodysplastic syndrome with clonal cytogenetic abnormalities followed by fatal erythroid leukemia after 14 years of exposure to hydroxyurea for sickle cell anemia

artículo científico publicado en 2015

Myeloid sarcoma of the nasopharynx mimicking an aggressive lymphoma

artículo científico publicado en 2013

Next-generation sequencing discriminates myelodysplastic/myeloproliferative neoplasms from paraneoplastic leukemoid reaction in cancer patients with hyperleukocytosis.

artículo científico publicado en 2017

Outcome of treatment after first relapse in younger adults with acute myeloid leukemia initially treated by the ALFA-9802 trial

artículo científico publicado en 2012

Phase I studies of AVE9633, an anti-CD33 antibody-maytansinoid conjugate, in adult patients with relapsed/refractory acute myeloid leukemia

artículo científico publicado en 2011

Platelet formation is the consequence of caspase activation within megakaryocytes

artículo científico publicado en 2002

Postinduction Minimal Residual Disease Predicts Outcome and Benefit From Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia With NPM1 Mutation: A Study by the Acute Leukemia French Association Group.

artículo científico publicado en 2016

Postremission treatment of elderly patients with acute myeloid leukemia in first complete remission after intensive induction chemotherapy: results of the multicenter randomized Acute Leukemia French Association (ALFA) 9803 trial

artículo científico publicado en 2007

Prevalence, clinical profile, and prognosis of NPM mutations in AML with normal karyotype

artículo científico publicado en 2005

Prognostic factors and outcome of patients with hematological malignancies in phase I trials: the Gustave Roussy scoring system

artículo científico publicado en 2017

Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine.

artículo científico publicado en 2010

Quantitation of isocitrate dehydrogenase (IDH)-induced D and L enantiomers of 2-hydroxyglutaric acid in biological fluids by a fully validated liquid tandem mass spectrometry method, suitable for clinical applications

artículo científico publicado en 2016

Randomized Phase II Study of Clofarabine-Based Consolidation for Younger Adults With Acute Myeloid Leukemia in First Remission

artículo científico publicado en 2017

Retrospective Study of Allogeneic Hematopoietic Stem Cell Transplantation in Philadelphia Chromosome-Positive Leukemia: 25 Years' Experience at Gustave Roussy Cancer Campus

artículo científico publicado en 2015

Secondary or concomitant neoplasms among adults diagnosed with acute lymphoblastic leukemia and treated according to the LALA-87 and LALA-94 trials

artículo científico publicado en 2007

Serum 2-hydroxyglutarate production in IDH1- and IDH2-mutated de novo acute myeloid leukemia: a study by the Acute Leukemia French Association group.

artículo científico publicado en 2013

Successful Outcome of DisseminatedFusariumInfection with Skin Localization Treated with Voriconazole and Amphotericin B-Lipid Complex in a Patient with Acute Leukemia ⬇️

artículo científico publicado el 1 de octubre de 2003

Superior long-term outcome with idarubicin compared with high-dose daunorubicin in patients with acute myeloid leukemia age 50 years and older

artículo científico publicado en 2012

TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia

scientific article published on October 2009

Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation

artículo científico publicado en 2013

Targeting primary acute myeloid leukemia with a new CXCR4 antagonist IgG1 antibody (PF-06747143).

artículo científico publicado en 2017

Treatment by Lenalidomide in lower risk myelodysplastic syndrome with 5q deletion--the GFM experience

artículo científico publicado en 2011

Treatment of newly diagnosed acute promyelocytic leukemia (APL): a comparison of French-Belgian-Swiss and PETHEMA results

artículo científico publicado en 2007

Treatment of older adults with acute promyelocytic leukaemia

artículo científico publicado en 2003

Tyrosine kinase inhibitors for the treatment of acute myeloid leukemia: delineation of anti-leukemic mechanisms of action

artículo científico publicado en 2011

Very long-term outcome of acute promyelocytic leukemia after treatment with all-trans retinoic acid and chemotherapy: the European APL Group experience

artículo científico publicado en 2009

When can real-time quantitative RT-PCR effectively define molecular relapse in acute promyelocytic leukemia patients? (Results of the French Belgian Swiss APL Group).

artículo científico publicado en 2009

Which AML subsets benefit from leukemic cell priming during chemotherapy? Long-term analysis of the ALFA-9802 GM-CSF study.

artículo científico publicado en 2010

[Prognostic factors in myelodysplasia syndromes]

artículo científico publicado en 2002

[Therapy-related acute myeloid leukemia: role of DNA repair]

artículo científico publicado en 2011

Lista de obras de Stéphane de Botton

A novel effect of DNA methyltransferase and histone deacetylase inhibitors: NFkappaB inhibition in malignant myeloblasts

AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic IDH2 Mutations.

Acute leukemia during pregnancy: a report on 37 patients and a review of the literature.

Additional chromosomal abnormalities in patients with acute promyelocytic leukaemia (APL) do not confer poor prognosis: results of APL 93 trial

An 18-case outbreak of drug-resistant Pseudomonas aeruginosa bacteriemia in hematology patients

An activating mutation in the CSF3R gene induces a hereditary chronic neutrophilia

Are PU.1 mutations frequent genetic events in acute myeloid leukemia (AML)?

Arsenic trioxide is required in the treatment of newly diagnosed acute promyelocytic leukemia. Analysis of a randomized trial (APL 2006) by the French Belgian Swiss APL group

Azacytidine in combination with tyrosine kinase inhibitors induced durable responses in patients with advanced phase chronic myelogenous leukemia.

BCOR and BCORL1 mutations in myelodysplastic syndromes and related disorders.

Central nervous system involvement in adult acute lymphoblastic leukemia at diagnosis and/or at first relapse: results from the GET-LALA group

Characterization of novel genomic alterations and therapeutic approaches using acute megakaryoblastic leukemia xenograft models

Chromosomal minimal critical regions in therapy-related leukemia appear different from those of de novo leukemia by high-resolution aCGH.

Clonal heterogeneity of acute myeloid leukemia treated with the IDH2 inhibitor enasidenib

Comparison of high-dose cytarabine and timed-sequential chemotherapy as consolidation for younger adults with AML in first remission: the ALFA-9802 study

Computer tomography in pulmonary invasive aspergillosis in hematological patients with neutropenia: an useful tool for diagnosis and assessment of outcome in clinical trials.

Concurrent Etoposide, Steroid, High-dose Ara-C and Platinum chemotherapy with radiation therapy in localised extranodal natural killer (NK)/T-cell lymphoma, nasal type.

Differentiation Syndrome Associated With Enasidenib, a Selective Inhibitor of Mutant Isocitrate Dehydrogenase 2: Analysis of a Phase 1/2 Study.

Discovery of AG-120 (Ivosidenib): A First-in-Class Mutant IDH1 Inhibitor for the Treatment of IDH1 Mutant Cancers.

Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML

Ecto-calreticulin in immunogenic chemotherapy

Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia

Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response

Erlotinib and gefitinib for the treatment of myelodysplastic syndrome and acute myeloid leukemia: a preclinical comparison

Erlotinib antagonizes ABC transporters in acute myeloid leukemia

Erlotinib exhibits antineoplastic off-target effects in AML and MDS: a preclinical study

Erratum to: Flt3 receptor inhibition reduces constitutive NFκB activation in high-risk myelodysplastic syndrome and acute myeloid leukemia

Favorable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia: a study from the Acute Leukemia French Association (ALFA)

Flt3 receptor inhibition reduces constitutive NFkappaB activation in high-risk myelodysplastic syndrome and acute myeloid leukemia

Hypomethylating agents reactivate FOXO3A in acute myeloid leukemia

IDH1 and IDH2 mutations as novel therapeutic targets: current perspectives

Immune stimulation during chemotherapy increases incidence of acute graft versus host disease in acute myeloid leukemia: A study on behalf of SFGM-TC and ALFA.

Impact of additional genetic alterations on the outcome of patients with NPM1-mutated cytogenetically normal acute myeloid leukemia.

Improved outcome of acute promyelocytic leukemia with high WBC counts over the last 15 years: the European APL Group experience.

Inherited transmission of the CSF3R T618I mutational hotspot in familial chronic neutrophilic leukemia

Invasive cutaneous infection due to Scopulariopsis brevicaulis unsuccessfully treated with high-dose micafungin in a neutropenic patient.

Is Cytarabine Useful in the Treatment of Acute Promyelocytic Leukemia? Results of a Randomized Trial From the European Acute Promyelocytic Leukemia Group

Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia

Liposomal amphotericin B in combination with caspofungin for invasive aspergillosis in patients with hematologic malignancies: a randomized pilot study (Combistrat trial).

Long-term follow-up of European APL 2000 trial, evaluating the role of cytarabine combined with ATRA and Daunorubicin in the treatment of nonelderly APL patients

Molecular determinants of immunogenic cell death: surface exposure of calreticulin makes the difference

Monitoring antibiotic-resistant enterobacteria faecal levels is helpful in predicting antibiotic susceptibility of bacteraemia isolates in patients with haematological malignancies.

Mutation allele burden remains unchanged in chronic myelomonocytic leukaemia responding to hypomethylating agents

Mutational profiling of isolated myeloid sarcomas and utility of serum 2HG as biomarker of IDH1/2 mutations

Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes.

Myelodysplastic syndrome with clonal cytogenetic abnormalities followed by fatal erythroid leukemia after 14 years of exposure to hydroxyurea for sickle cell anemia

Myeloid sarcoma of the nasopharynx mimicking an aggressive lymphoma

Next-generation sequencing discriminates myelodysplastic/myeloproliferative neoplasms from paraneoplastic leukemoid reaction in cancer patients with hyperleukocytosis.

Outcome of treatment after first relapse in younger adults with acute myeloid leukemia initially treated by the ALFA-9802 trial

Phase I studies of AVE9633, an anti-CD33 antibody-maytansinoid conjugate, in adult patients with relapsed/refractory acute myeloid leukemia

Platelet formation is the consequence of caspase activation within megakaryocytes

Postinduction Minimal Residual Disease Predicts Outcome and Benefit From Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia With NPM1 Mutation: A Study by the Acute Leukemia French Association Group.

Postremission treatment of elderly patients with acute myeloid leukemia in first complete remission after intensive induction chemotherapy: results of the multicenter randomized Acute Leukemia French Association (ALFA) 9803 trial

Prevalence, clinical profile, and prognosis of NPM mutations in AML with normal karyotype

Prognostic factors and outcome of patients with hematological malignancies in phase I trials: the Gustave Roussy scoring system

Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine.

Quantitation of isocitrate dehydrogenase (IDH)-induced D and L enantiomers of 2-hydroxyglutaric acid in biological fluids by a fully validated liquid tandem mass spectrometry method, suitable for clinical applications

Randomized Phase II Study of Clofarabine-Based Consolidation for Younger Adults With Acute Myeloid Leukemia in First Remission

Retrospective Study of Allogeneic Hematopoietic Stem Cell Transplantation in Philadelphia Chromosome-Positive Leukemia: 25 Years' Experience at Gustave Roussy Cancer Campus

Secondary or concomitant neoplasms among adults diagnosed with acute lymphoblastic leukemia and treated according to the LALA-87 and LALA-94 trials

Serum 2-hydroxyglutarate production in IDH1- and IDH2-mutated de novo acute myeloid leukemia: a study by the Acute Leukemia French Association group.

Successful Outcome of DisseminatedFusariumInfection with Skin Localization Treated with Voriconazole and Amphotericin B-Lipid Complex in a Patient with Acute Leukemia ⬇️

Superior long-term outcome with idarubicin compared with high-dose daunorubicin in patients with acute myeloid leukemia age 50 years and older

TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia

Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation

Targeting primary acute myeloid leukemia with a new CXCR4 antagonist IgG1 antibody (PF-06747143).

Treatment by Lenalidomide in lower risk myelodysplastic syndrome with 5q deletion--the GFM experience

Treatment of newly diagnosed acute promyelocytic leukemia (APL): a comparison of French-Belgian-Swiss and PETHEMA results

Treatment of older adults with acute promyelocytic leukaemia

Tyrosine kinase inhibitors for the treatment of acute myeloid leukemia: delineation of anti-leukemic mechanisms of action

Very long-term outcome of acute promyelocytic leukemia after treatment with all-trans retinoic acid and chemotherapy: the European APL Group experience

When can real-time quantitative RT-PCR effectively define molecular relapse in acute promyelocytic leukemia patients? (Results of the French Belgian Swiss APL Group).

Which AML subsets benefit from leukemic cell priming during chemotherapy? Long-term analysis of the ALFA-9802 GM-CSF study.

[Prognostic factors in myelodysplasia syndromes]

[Therapy-related acute myeloid leukemia: role of DNA repair]